Quetiapine vs Haloperidol for Schizophrenia Treatment

Efficacy and Safety Considerations

The American Academy of Child and Adolescent Psychiatry notes that haloperidol at 0.02-0.12 mg/kg was superior to placebo in youth, though direct adult dose comparisons favor quetiapine's broader therapeutic range 1
The American Academy of Child and Adolescent Psychiatry recommends prioritizing medications with established safety and efficacy in youth, noting that atypical antipsychotics are generally favored over traditional neuroleptics due to lower EPS risk 1

Quetiapine causes modest weight gain of approximately 2.1 kg in short-term trials, which the American Academy of Child and Adolescent Psychiatry identifies as a significant clinical issue with atypical antipsychotics 2
Both agents can prolong QTc interval, though neither typically exceeds 500 ms at therapeutic doses 3

If insufficient response after 6 weeks at adequate doses, switch to a different antipsychotic agent 2
Baseline assessment should include physical examination for movement disorders, weight, metabolic parameters, renal and hepatic function, and ECG 5
Ongoing monitoring should assess EPS regularly, weight and metabolic parameters, and liver enzymes if obesity develops 5

The American Academy of Child and Adolescent Psychiatry notes that youth with early-onset schizophrenia may be less likely to respond adequately to any medication therapy due to association between treatment resistance and earlier age of onset 1
Long-term use of antipsychotics in early-onset schizophrenia has not been extensively studied, making ongoing monitoring essential 4
Individual response variability exists, and some patients may respond better to haloperidol despite overall evidence favoring quetiapine 2